Latest News

Covagen nominates bispecific TNF/IL-17A inhibitor as drug candidate to enter preclinical development

Zürich-Schlieren, Switzerland, December 12, 2011.  Covagen announced today that it is entering preclinical development with its first drug candidate, a first-in-class bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases such as rheumatoid arthritis (RA), psoriasis and

Seroba Co-leads a €1.2 million New Investment in Biosensia.

Dublin, Ireland, 9 November 2011.  Biosensia, a point of care diagnostics company, has secured €1.2 million in new funding as part of the company’s plans to advance its regulatory and commercial strategy for its platform in Europe and the US. The funding round was co-led by Seroba

Seroba Kernel Co-leads £5m Investment in Veryan Medical.

Dublin, Ireland, November 1, 2011. Seroba Kernel Life Sciences (Seroba Kernel) and Imperial Innovations Group (Innovations) have co-led a £5m funding round into Veryan Medical, which is developing innovative solutions for vascular disease using its unique Biomimics 3D™ stent technology.